Vyvanse lisdexamfetamine regulatory update

FDA approved an expanded label for Vyvanse lisdexamfetamine to treat ADHD to include the use in children ages 13-17. The prodrug of amphetamine is marketed by Shire to treat ADHD in children ages 6-12...